Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

Cancer Journal

Volumn 9, Issue 1, 2003, Pages 58-66

  Nemunaitis, John J ^a,c,e   Orr, Douglas ^a,b   Eager, Rob ^c   Cunningham, C Casey ^a,c   Williams, Adrienne ^a,c   Mennel, Robert ^a,b   Grove, William ^d   Olson, Stephen ^d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Mary Crowley Medical Research Center   (United States)

^d PFIZER INC   (United States)

^e Collins Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; GEMCITABINE; ACETYLDINALINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PHENYLENEDIAMINE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APNEA; ARTICLE; ASTHENIA; BLEEDING; CACHEXIA; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; CONSTIPATION; DEHYDRATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; EPISTAXIS; FATIGUE; FECES IMPACTION; FEMALE; HUMAN; HYPOTENSION; KIDNEY FAILURE; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OLIGURIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TENESMUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY URGENCY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PHENYLENEDIAMINES; RIBONUCLEOTIDE REDUCTASES;

EID: 0038284073     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200301000-00010     Document Type: Article

References (57)

1. Berger MR, Richter H, Seeling MH et al. New cytostatics: More activity and less toxicity. Cancer Treat Rev 1990;17:143-154.
2. Howard CT, Roberts BJ, Vincent PW. N-acetyl-dinaline. A small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 1992;33:393.
3. Corbett T, Valeriote F, LoRusso P. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacol 1995;33:102-122.
4. LoRusso PM, Demchik L, Foster B et al. Preclinical activity of CI-994 (acetyldinaline; PD 123654). Inv New Drugs 1996;14:349-356.
5. el-Beltagi HM, Martens ACM, Lelieveld P et al. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells - preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res 1993;53:3008-3014.
6. el-Beltagi HM, Martens ACM, Dahab GM et al. Efficacy of acetyldinaline for treatment ofminimal residual disease (MRD): Preclinical studies in the BNML rat model for human acute myelocytic leukemia. Leukemia 1993;7:1795-1800.
7. Graziano MJ, Pilcher GD, Walsh KM. Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs. Inv New Drugs 1997;15:295-310.
8. Rummel SA, Kraker AJ, Steinkampf RW et al. Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int J Cancer 1995;62:636-642.
9. Berger MR, Schmahl D. Antineoplastic activity of two 4-amino-N(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat mammary carcinoma. Proc Am Assoc Cancer Res 1987;28:301.
10. Berger MR, Schmahl D. Comparative antineoplastic activity of two 4-amino-N(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat mammary carcinoma. Proc Am Assoc Cancer Res 1989;30:579.
11. Berger MR, Seeling MH, Schmahl D. Antineoplastic activity of 4-amino-N(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat colorectal carcinoma. Proc Am Assoc Cancer Res 1990;31:414.
12. Wulf G, Falk H, Weiershausen U. Cytostatic activity and potential mechanism of action of 4-amino-N-(2′-amino-phenyl)benzamide (dinaline) on Adriamycin sensitive (FL) and resistant (ARN) Friend leukemia cells. J Cell Pharmacol 1990;1:109-117.
13. Hagenbeek A, Weiershausen U, Martens AC. Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). Leukemia 1988;2:226-230.
14. Kraker AJ, Wolven A, Fry DW. Cell cycles and nucleotide metabolism effects a 4-(acetylamino)-N-(2-aminophenyl) benzamide (PD 123654, GOE 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 1991;32:396.
15. Graziano MJ, Galati AJ, Walsh KM. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol 1999;73:168-174.
16. Kraker AJ, Hartl BG, Miin J. Effect of CI-994 (N-acetyl dinaline or 4-(acetylamino)-N-(2-aminophenyl)benzamide) on histone acetylation and differentiation in HCT-8 colon carcinoma cells [abstract #809]. AACR Proc 1999;40:121.
17. LoRusso PM, Wozniak A, Foster B. Phase I clinical trial of CI-Sci 994. Proc ASCO 1997;16:745a.
18. Wozniak A, O'Shaughnessy J, Fiorica J. Phase II trial of CI-994 (GOE-5549) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 1999;18:487a.
19. O'Shaughnessy J, Flaherty L, Fiorica J. Phase II trial of CI-994 in patients with metastatic renal cell carcinoma. Proc ASCO 1999;18:349a.
20. Erlichman C. Novel chemotherapeutic agents in clinical development. Curr Opin Oncol 1991;3:1037-1042.
21. Zalupski J. Phase II trial of CI-994 in patients with advanced pancreatic cancer. Proc ASCO 2000;19:1115a.
22. Howard CT. In vitro antitumor activity of CI-994 (N-acetyl-dinaline, GEO 5549) alone and in combination with gemcitabine against LC-12 squamous cell lung carcinoma. Proc Am Assoc Cancer Res 1999;40:3893.
23. Hansen HH, Sorensen JB. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review. Semin Oncol 1997;24[2 suppl 7]:38-41.
24. Chavalier T. Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol 1996;23[5 suppl 10]:36-42.
25. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin vs. cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18(1):122-130..
26. Burris HA, Moore MJ, Andersen J et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
27. Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer: role of gemcitabine. Digestion 1997;58:503-507.
28. van Moorsel CJ, Kroep JR, Pinedo HM et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999;10:441-448.
29. Ng HH, Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci 2000;25:121-126.
30. Penn LD, Cohen LH, Olson SC, Rossi DT. LC/MS/MS quantitation of an anti-cancer drug in human plasma using a solid-phase extraction workstation: application to population pharmacokinetics. J Pharm Biomed Anal 2001; 25:569-576.
31. Beal SL, Sheiner LB. NONMEM User Guide: Part I-VII, 1992.
32. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-174.
33. Shin J-Y, Kim H-S, Park J et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000;60:262-265.
34. Mahlknecht U, Ottmann OG, Hoelzer D. When the band begins to play: histone acetylation caught in the crossfire of gene control. Mol Carcinog 2000;27:268-271.
35. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-48.
36. Spencer VA, Davie JR. Role of covalent modifications of histone in regulating gene expression. Gene 1999;240:1012.
37. Loidl P. Histone acetylation: facts and questions. Chromosome 1994;103:441-449.
38. Wolffe AP, Pruss D. Targeting chromatin disruption: transcription regulators that acetylate histones. Cell 1996;84:817-819.
39. Wang J, Hoshino T, Redner RL et al. ETO, fusion partner in t(8; 21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad CISci USA 1998;95:10860-10865.
40. Cameron EE, Bachman KE, Myohanen S et al. Synergy of dimethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
41. Le Beau MM, Espinosa R, Neuman WL et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid disease. Proc Natl Acad Sci USA 1993;90:5484-5488.
42. Mahlknecht U, Bucala R, Hoelzer D et al. High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region. Cytogenet Cell Genet 1999;86:237-239.
43. Aguiar RC, Chase A, Coulthard S et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 1997;90:3130-3135.
44. Taki T, Sako M, Tsuchida M et al. The t(11;16)-(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997;89:3945-3950.
45. Cohn KH, Ornstein DL,Wang F. Chromosome3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 1997;71:20-25.
46. van der Hout AH, van der Vlies P, Wijmenga C et al. The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. Genomics 1991;11:437-442.
47. Muraoka M, Konishi M, Kikuchi-Yanohita R et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996;12:1565-1569.
48. Giles RH, Peters DJM, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998;14:178-183.
49. Parke Davis Pharmaceutical Research Division ofWarner-Lambert Company. Investigator's Brochure. June 9, 2000 edition.
50. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytosine deaminase. Biochem Pharmacol 1993;45:1857-1861.
51. Laliberte J, Marquez VE, Momparler RL. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 1992;30:7-11.
52. Cacciamani T, Vita A, Cristalli G et al. Purification of human cytidine deaminase: molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs. Arch Biochem Biophys 1991;290:285-292.
53. Jeong LS, Buenger G, McCormack JJ et al. Carbocyclic analogues of the potent cytidine deaminase inhibitor 1-(beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine). J Med Chem 1998;41:2572-2578.
54. Fry DW. Cytotoxic synergism between trimetrexate and etoposide: evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations. Biochem Pharmacol 1990;40:1981-1988.
55. Fry DW, Boritzki TJ, Besserer JA et al. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra [1,9-cd]pyrazole-6-(2H)-one (anthrapyrazoles). Biochem Pharmacol 1985;34:3499-3508.
56. Storniolo AM, Allerheiigen SRB, Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997;24:s72-s77.
57. Chen WY, Townes TM. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromation condensation. Proc Natl Acad Sci USA 2000;97:377-382.